{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG|Designated/Withdrawn" in comments (approximate match)
Status:
Investigational
Source:
NCT00537381: Phase 2 Interventional Completed Prostatic Neoplasms
(2007)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01101581: Phase 1/Phase 2 Interventional Withdrawn Non Hodgkin's Lymphoma
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00989586: Phase 1/Phase 2 Interventional Completed Lymphoma
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00001269: Phase 1 Interventional Completed Breast Neoplasms
(1991)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01205438: Phase 3 Interventional Completed Systemic Lupus Erythematosus
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00992186: Phase 2 Interventional Completed Prostate Cancer
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00076986: Phase 3 Interventional Completed Glioblastoma Multiforme
(2004)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00217815: Phase 1/Phase 2 Interventional Completed Cancer of the Breast
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00024934: Phase 1 Interventional Completed IgA Deficiency
(2001)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00738582: Phase 2 Interventional Completed Malignant Pleural Mesothelioma
(2008)
Source URL:
Class:
PROTEIN